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BACKGROUND:
Despite 10% of the population reporting a penicillin "allergy", less than 1% of the population are confirmed as being truly penicillin allergic by formal testing [1] [2] [3] [4] [5] . In Australia, the prevalence of antimicrobial allergy labels in hospitalised inpatients is 18% and higher in populations with more frequent antibiotic use (e.g. immunocompromised hosts) 6, 7 . Antimicrobial allergy labels are associated with broad spectrum antibiotic usage, antimicrobial resistance, inappropriate prescribing, morbidity and mortality 4, 7, 8 . The majority of antibiotic allergy labels reflect either pharmacologically predictable side effects or mild non-immunologically mediated drug reactions that are amendable to rechallenge or symptomatic management as necessary 9, 10 . Antibiotic allergy testing (AAT), which combines skin prick testing (SPT), intradermal testing (IDT) and ingestion (usually oral) challenge, has a high negative-predictive value and can therefore accurately de-label patients previously suspected to have an allergy on clinical criteria alone 1, 11, 12 . In an era of increasing antimicrobial resistance, a strategic approach for clinicians to confirm and reliably document antibiotic allergy labels is required.
AIMS:
To identify the need for and potential barriers to development of coordinated multidisciplinary AAT programs in Australia & New Zealand we surveyed current knowledge and approaches to antibiotic allergy testing among allergists, clinical immunologists, infectious diseases physicians, general physicians, and hospital pharmacists.
METHODS:
Studied population
We targeted healthcare providers most closely involved with the diagnosis and management of antibiotic allergies and adverse drug reaction reporting in Australian and New Zealand. These included allergists/clinical immunologists, infectious diseases physicians, general physicians and hospital pharmacists.
Survey tool
A 37-item multiple-choice survey was developed to assess the key antibiotic allergy domains: (a) 
Survey distribution
An invitation and link to the survey was distributed via online modalities only, including RACP weekly e-bulletin (n = 13,016), SHPA e-bulletin (n = 2550), ASCIA e-bulletin (n = 320), ASID weekly e-bulletin (n = 778) and Ozbug mailing list (n = 800 A p-value of <0.05 was deemed statistically significant.
RESULTS:
A total of 277 persons completed the survey. This article is protected by copyright. All rights reserved.
Accepted Article patients per week with a penicillin allergy, with a further 21% (58/277) reviewing 6-10 patients per week.
(b) Allergy testing practices
Whilst 32% (67/208) indicated they already employed allergy testing, 42% (118/277) of respondents were either unaware of or did not have AAT services available to them (Figure 1 ). Antibiotic allergy services were available equally to those with < 10 years or ≥ 10 years clinical experience (p =0.63).
Varied skin testing practices were available to respondents (Figure 1) . The allergy phenotypes referred for AAT are demonstrated in (e) Clinician knowledge regarding antibiotic allergy
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The responses to questions regarding the prevalence of penicillin allergy and mechanisms of crossreactivity are summarised in Table 3 . There was no difference in understanding of penicillin and betalactam cross-reactivity comparing those with < 10 and ≥ 10 years experience (Figure 3) . 
DISCUSSION:
In the current era of increasing antimicrobial resistance, opportunities to improve antibiotic prescribing are essential. Attention has turned to antibiotic allergy de-labelling to enhance AMS programs 14 .
Before de-labelling can be incorporated into AMS, assessments of current Australian and New
Zealand antibiotic allergy service provisions and stakeholder knowledge are required to identify the barriers to implementing multi-disciplinary AAT services. We surveyed Australian and New Zealand clinicians and pharmacists to examine the current and future requirements of AAT programs and attitudes toward antibiotic allergy.
Our survey highlights a demand for AAT amongst key stakeholders irrespective of clinical experience, contrasted with significant operational barriers. Whilst antibiotic allergies encountered by infectious diseases physicians are being increasingly found to impact on antibiotic selection, antibiotic appropriateness and antimicrobial resistance 6, 8, 15 , less than half infectious diseases specialists had AAT available, likely reflective of poor access. When available, testing to a vast array of β-lactams, including the implicated antibiotic, was offered. There appears a desire to refer patients with a history of immediate hypersensitivity over delayed, potentially reflecting a perception of less robust options for the management and diagnosis for T-cell mediated reactions. This is interesting as antibiotics contribute almost 50% of severe cutaneous adverse reactions 16 , and both in vivo (skin testing) and ex vivo diagnostics are continually improving [17] [18] [19] . In addition clinical phenotyping and risk stratification is even more important for many serious delayed reactions to avoid future morbidity and mortality related to re-exposure to a suspect drug or one that is structurally related. Most respondents were optimistic that overall AAT could aid AMS and, if more easily accessible, would employ AAT in their AMS programs.
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We identified significant knowledge gaps among surveyed clinicians and pharmacists that did not correlate with years of clinical experience. Compounding either a true or perceived absence of AAT, is a potential misunderstanding of antibiotic allergy, previously noted in the US 20 . Whilst historical estimates of IgE mediated cephalosporin and penicillin cross-reactivity were 15-25%, more contemporary studies suggest the true rate of cross-reactivity to be <2% and potentially lower for third and later generation cephalosporins [21] [22] [23] . Recent studies suggest the rate of immediate carbapenem and penicillin allergy cross-reactivity to be also extremely low (<1%) 24, 25 . This contrasts with our surveyed stakeholders, 78% of whom suggested a cephalosporin cross-reactivity rate > 2% and 58%, a meropenem cross-reactivity of > 1%. Furthermore, despite most childhood-onset MPE being secondary to viral exanthema or antibiotic/viral interaction 26, 27 rather than antibiotic exposure, clinicians and pharmacists were reluctant to administer a preferred penicillin therapy in these patients immunologists, pharmacists and infectious diseases physicians. Similar multidisciplinary models in cancer patient AMS programs, engaging relevant clinicians, have lead to significant improvements in quality of care and mortality benefits 31 . Improved knowledge of antibiotic allergy and the role ATT will help promote allergy services as a safe and effective service.
CONCLUSION:
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Despite a high antibiotic allergy label prevalence and demand for AAT services, current implementation barriers include lack of access to appropriate specialist healthcare providers to carry out AAT as well as cost of delivery. A collaborative model of infectious diseases physicians, pharmacists and allergists/clinical immunologists would enable targeted AAT delivery to those that require it, improving antibiotic utilisation, choice and drug safety. Current knowledge gaps suggest that education of clinicians and pharmacists and engagement of allergy and infectious diseases networks will be needed to provide the change necessary to fuel such multidisciplinary service models. Accepted Article This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
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